CD8A and COVID-19: Among the 10 and 12 putative SARS-CoV-2-specific and expanded groups, we further chose those that include clones from ≥3 different COVID-19 patients with ≥55% clones having more than one cell, resulting in five and two groups for CD8+ and CD4+ T cells, respectively.